Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

Key Points Question Compared with sorafenib, is atezolizumab plus bevacizumab cost-effective as first-line treatment of unresectable hepatocellular carcinoma? Findings In this economic evaluation using a partitioned survival model, therapy with atezolizumab plus bevacizumab generated incremental benefit over sorafenib as measured by quality-adjusted life-years but was not cost-effective at a willingness-to-pay threshold of $150 000 per quality-adjusted life-year. However, some patients may achieve preferred economic outcomes from atezolizumab plus bevacizumab therapy by tailoring the regimen based on individual patient factors. Meaning The findings suggest that atezolizumab plus bevacizumab may be a valuable therapy for unresectable hepatocellular carcinoma but may become more cost-effective with price reductions.